alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>

                                                                  EXHIBIT 10.2

March 15, 1999

Mr. Bruce Hayden
3396 Fallen Wood Cove
Collierville, Tennessee 38017

Dear Bruce:

As follow-up to our conversation late last week, UroCor is pleased to extend 
you an offer to join the company as Senior Vice President, Chief Financial 
Officer, effective April 12, 1999. This position will report both to Mike 
George and myself.

Initial annual base salary will be $185,000 paid on a bi-weekly basis. At the 
conclusion of 12 months, you will be eligible for a performance and 
compensation review. A bonus opportunity of 30% of base salary will be 
available based on corporate performance to revenue, operating income and 
cash flow objectives. This bonus program is paid based on full year 
performance and will be prorated based on number of months in the position. 
From an incentive stock option perspective, you will be eligible for 75,000 
shares. These shares will vest equally over a 4 year period in 12 month 
increments (i.e. 25% per year). The price for these options will be based on 
the closing price of UroCor's stock on April 12, 1999. The exercise period 
will be 10 years.

From a re-location perspective, as we discussed, UroCor will make available 
up to $7,500 for physical moving expenses, up to $25,000 in selling expenses 
and up to $5,000 in buying expenses. Additionally, UroCor will make available 
up to 3 months of temporary living expenses.

UroCor also has a 401K program which provides for a 50% match up to 6% of an 
employees base (available after first 12 months). Further, the Company has a 
stock purchase plan which allows employees to acquire stock at 15% below 
market price. The company also has a standard medical, dental and life 
insurance program. The details of this plan will be provided shortly. We 
allow 3 weeks vacation for years 1-5 of employment and 4 weeks vacation after 
6 years.

As with all employees, your employment is "at will", and as such, this offer 
does not represent a contract. Your first 90 days of employment are 
considered an introductory period. As discussed, UroCor has a Change in 
Control provision which provides for 18 months protection. In the 
unanticipated event of termination without cause, the Company would provide 
up to 9 months base salary. Every employee is required to sign a 
Confidentiality and Non-Compete Agreement with UroCor at the time of 
employment. Last, this offer will need to be ratified by UroCor's Board of 
Directors.

Bruce, I am very excited about the prospect of your joining UroCor and 
believe you will make a significant impact throughout the organization. If 
you have questions, please do not hesitate to contact me at (405) 290-4110.

Sincerely,

/s/ William A. Hagstrom

William A. Hagstrom
Chairman of the Board
and Chief Executive Officer
EXHIBIT
      32.1







**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**




In
      connection with the Quarterly Report of Preferred Voice, Inc. (the "Company")
      on
      Form 10-QSB for the period ending December 31, 2007 as filed with the Securities
      and Exchange Commission on the date hereof (the "Report"), I, Mary G. Merritt,
      Principal Executive Officer and Principal Financial Officer of the Company,
      certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
      Sarbanes-Oxley Act of 2002, that:




(1)
            The
                Report fully complies with the requirements of section 13(a) or 15(d)
                of
                the Securities Exchange Act of 1934;
                and




(2)
            The
                information contained in the Report fairly presents, in all material
                respects, the financial condition and result of operations of the
                Company.








/s/
      Mary
      G. Merritt


Mary
      G.
      Merritt


Principal
      Executive Officer


Principal
      Financial Officer


February
      13, 2008
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF CONSOLIDATED OPERATIONS AND
ACCUMULATED DEFICIT ON PAGES 2 AND 3 OF THE COMPANY'S FORM 10-Q FOR THE
QUARTERLY PERIOD ENDING JUNE 30, 1999, AND IS QUALIFIED IN ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1999
<CASH>                                          15,349
<SECURITIES>                                    22,302
<RECEIVABLES>                                    5,917
<ALLOWANCES>                                         0
<INVENTORY>                                      1,085
<CURRENT-ASSETS>                                44,706
<PP&E>                                         197,491
<DEPRECIATION>                                     565
<TOTAL-ASSETS>                                 258,857
<CURRENT-LIABILITIES>                            6,933
<BONDS>                                        110,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       225,805
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   258,857
<SALES>                                            308
<TOTAL-REVENUES>                                 2,711
<CGS>                                            1,662
<TOTAL-COSTS>                                    9,445
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (6,734)
<INCOME-TAX>                                        20
<INCOME-CONTINUING>                            (6,764)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (6,171)
<EPS-BASIC>                                     (0.16)
<EPS-DILUTED>                                   (0.16)




</TABLE>
# C_2023024EN.01003901.xml

| 23.1.2023 | EN | Official Journal of the European Union | C 24/39 |
| --- | --- | --- | --- |

23.1.2023

EN

Official Journal of the European Union

C 24/39

---

Order of the General Court of 8 November 2022 — Grupa ‘Lew’ v EUIPO — Lechwerke (GRUPALEW.)

(Case T-672/21) (1)

(EU trade mark - Opposition proceedings - International registration designating the European Union - Figurative mark GRUPALEW. - Earlier national figurative mark LEW - Relative grounds for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) - Proof of genuine use - Article 10(1) of Delegated Regulation (EU) 2018/625 - Article 71(1) of Delegated Regulation 2018/625 - Action manifestly lacking any foundation in law)

(2023/C 24/53)

Language of the case: German

Parties

Applicant: Grupa ‘LEW’ S.A. (Częstochowa, Poland) (represented by: A. Korbela, lawyer)

Defendant: European Union Intellectual Property Office (represented by: M. Eberl and E. Markakis, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Lechwerke AG (Augsburg, Germany) (represented by: N. Gerling, lawyer)

Re:

By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 17 August 2021 (Case R 2763/2019-4).

Operative part of the order

| 1. | The action is dismissed. |
| --- | --- |

1.

The action is dismissed.

| 2. | Grupa ‘LEW’ S.A. shall bear its own costs and pay those incurred by the European Union Intellectual Property Office (EUIPO). |
| --- | --- |

2.

Grupa ‘LEW’ S.A. shall bear its own costs and pay those incurred by the European Union Intellectual Property Office (EUIPO).

| 3. | Lechwerke AG shall bear its own costs. |
| --- | --- |

3.

Lechwerke AG shall bear its own costs.

---

(1)  OJ C 502, 13.12.2021.

---
EXHIBIT 21.1

                      NETWORK EQUIPMENT TECHNOLOGIES, INC.

                     Wholly-Owned Subsidiaries of Registrant

                               as of June 16, 2001

N.E.T. APLA, Inc.                      (State of Incorporation: Delaware)

N.E.T. China, Inc.                     (State of Incorporation: Delaware)

N.E.T. Credit Corporation              (State of Incorporation: California)

N.E.T. Europe Ltd.                     (Incorporated Under the Laws of England)

N.E.T. Europe S.A.                     (Incorporated Under the Laws of France)

N.E.T. Federal, Inc.                   (State of Incorporation: Delaware)

N.E.T. International, Inc              (Incorporated Under the Laws of Barbados)

N.E.T. Japan, Inc                      (State of Incorporation: Delaware)

NetDotCom Broadband Technologies Inc.  (Incorporated Under the Laws of Canada)

Network Equipment Technologies
 Europe GmbH                           (Incorporated Under the Laws of Germany)

FlowWise Networks, Inc.                (State of Incorporation: California)
Exhibit
10.27


 





 


	 


 


February
23, 2021


 


David
Humphrey





Via
email:


 


	Re:
    	Offer
    Letter February 11, 2021 Amendment


 


Dear
Dave:


 


This
letter is to amend the Equity Award language of the fully executed February 11, 2021 Offer Letter from “Once the contemplated
merger transaction closes you will be provided a stock option grant in a quantity representing 1.0% of the merged Company’s
newly formed Equity Incentive Plan (the “Plan”). To “Once the contemplated merger transaction closes you will
be provided a stock option grant of 275,000 shares of the merged Company’s newly formed Equity Incentive Plan (the “Plan”).


 


All
other language in the February 11, 2021 Offer letter will remain the same.


 


Sincerely,








 


	/s/ Lynn Kirkpatrick	 
	Lynn Kirkpatrick	 
	Chief Executive Officer	 


 


Acknowledged:


 


	/s/ David Humphrey	 
	Dave Humphrey	 


 


02/23/2021


Date


 


Ensysce
Biosciences Inc.


7946
Ivanhoe Ave. Ste 201 - La Jolla, CA – 92037 www.ensysce.com
# C_2021320EN.01003101.xml

| 9.8.2021 | EN | Official Journal of the European Union | C 320/31 |
| --- | --- | --- | --- |

9.8.2021

EN

Official Journal of the European Union

C 320/31

---

Request for a preliminary ruling from the Østre Landsret (Denmark) lodged on 28 May 2021 — A1 and A2 v I

(Case C-352/21)

(2021/C 320/32)

Language of the case: Danish

Referring court

Østre Landsret

Parties to the main proceedings

Appellants: A1 and A2

Respondents: I

Question referred

Must Article 15(5) of the Brussels I Regulation, (1) in conjunction with Article 16(5) thereof, be interpreted as meaning that hull insurance for pleasure craft that are not used for commercial purposes falls within the exception laid down in Article 16(5) of that regulation, and is, therefore, an insurance contract which contains a choice of court agreement departing from the rule laid down in Article 11 of that regulation valid under Article 15(5) of that regulation?

---

(1)  Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters (OJ 2012 L 351, p. 1).

---
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                             140
<SECURITIES>                                         0
<RECEIVABLES>                                       87
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                   298
<PP&E>                                             174
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                   3,386
<CURRENT-LIABILITIES>                            1,676
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                         14
<COMMON>                                            61
<OTHER-SE>                                       1,411
<TOTAL-LIABILITY-AND-EQUITY>                     3,386
<SALES>                                            745
<TOTAL-REVENUES>                                   745
<CGS>                                               75
<TOTAL-COSTS>                                    7,181
<OTHER-EXPENSES>                                    61
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (17,325)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (17,325)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (17,325)
<EPS-BASIC>                                     (2.93)
<EPS-DILUTED>                                   (2.93)


</TABLE>
# C_2022294EN.01002702.xml

| 1.8.2022 | EN | Official Journal of the European Union | C 294/27 |
| --- | --- | --- | --- |

1.8.2022

EN

Official Journal of the European Union

C 294/27

---

Judgment of the General Court of 8 June 2022 — Darment v Commission

(Case T-92/21) (1)

(Environment - Regulation (EU) No 517/2014 - Fluorinated greenhouse gases - Electronic registry for quotas for placing hydrofluorocarbons on the market - Decision to register - Authorisation to use a quota - Compliance with a judgment of the General Court - Principle of sound administration)

(2022/C 294/39)

Language of the case: English

Parties

Applicant: Darment Oy (Helsinki, Finland) (represented by: C. Ginter, lawyer)

Defendant: European Commission (represented by: E. Sanfrutos Cano, K. Talabér-Ritz and B. De Meester, acting as Agents)

Re:

By its application under Article 263 TFEU, the applicant, Darment Oy, seeks the annulment of the European Commission’s decision of 15 December 2020 to enter its quota for the year 2021 and for the years 2019 and 2020 in the electronic registry for quotas for placing hydrofluorocarbons (HFCs) on the market (‘the HFC registry’) (‘the contested decision’).

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Darment Oy to pay the costs, including those relating to the proceedings for interim measures. |
| --- | --- |

2.

Orders Darment Oy to pay the costs, including those relating to the proceedings for interim measures.

---

(1)  OJ C 128, 12.4.2021.

---
# C_2021391EN.01001301.xml

| 27.9.2021 | EN | Official Journal of the European Union | C 391/13 |
| --- | --- | --- | --- |

27.9.2021

EN

Official Journal of the European Union

C 391/13

---

Appeal brought on 14 July 2021 by Biogen Netherlands BV against the judgment of the General Court (Seventh Chamber, Extended Composition) delivered on 5 May 2021 in Case T-611/18, Pharmaceutical Works Polpharma v EMA

(Case C-439/21 P)

(2021/C 391/19)

Language of the case: English

Parties

Appellant: Biogen Netherlands BV (represented by: C. Schoonderbeek, advocaat)

Other parties to the proceedings: Pharmaceutical Works Polpharma S.A., European Medicines Agency, European Commission

Form of order sought

The Appellant claims that the Court should:

| — | grant the appeal; |
| --- | --- |

—

grant the appeal;

| — | set aside the judgment under the appeal. |
| --- | --- |

—

set aside the judgment under the appeal.

Pleas in law and main arguments

First ground of appeal: the General Court misapplied Article 277 TFEU by failing to recognize that the plea of illegality raised against the Commission’s decision of 30 January 2014 granting marketing authorisation for the medicinal product Tecfidera was inadmissible because that decision could have been challenged directly by Polpharma since it is a regulatory act that does not entail implementing measures and was of direct concern to Polpharma.

Second ground of appeal: in its assessment of the plea of illegality, the General Court misinterpreted and misapplied the concept of the global marketing authorisation laid down in Article 6(1) of Directive 2001/83/EC (1).

Third ground of appeal: the General Court misinterpreted the legal requirements for the authorisation of combination medicinal products in 1994 and failed to recognize the renewal of the Fumaderm authorisation in 2013 in its consideration of the issue.

Fourth ground of appeal: the General Court misinterpreted and misapplied the principle of mutual recognition of assessments and decisions adopted by national authorities by concluding that, in the case at hand, this principle did not apply to the EMA and Commission.

Fifth ground of appeal: the General Court misapplied the applicable standard of judicial review in relation to scientific assessments and scientific evidence by making its own assessment of the scientific data in the file.

---

(1)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001, L 311, p. 67).

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

                    Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, August 6, 2018, 10:00 a.m. to August 6, 2018, 05:00 p.m., National Cancer Institute Shady Grove, 9609 Medical Center Drive, 7W102, Rockville, MD 20850 which was published in the                     **Federal Register**                     on June 08, 2018, 83 FR 26703.                          ( print page 32673)    

This meeting notice is amended to change the contact person from Dr. Shakeel Ahmad to Dr. Jun Fang. The meeting date has changed from August 6, 2018 to August 16, 2018. The meeting room has changed from 7W102 to 7W246. The meeting times are the same. The meeting is closed to the public.

Dated: July 10, 2018.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018-15044 Filed 7-12-18; 8:45 am]

BILLING CODE 4140-01-P
#### STATE of Louisiana v. Willie L. VEAL.

No. 60629.

Supreme Court of Louisiana.

Feb. 10, 1978.

Paul D. White, Jr., Provosty & Sadler, Alexandria, for defendant-appellant.

William J. Guste, Jr., Atty. Gen., Barbara Rutledge, Asst. Atty. Gen., Edwin 0. Ware, Dist. Atty., Edward E. Roberts, Jr., Asst. Dist. Atty., for plaintiff-appellee.

PER CURIAM.

Affirmed.
260 La. 699

#### Oscar Lionel SMITH v. LOUISIANA BANK & TRUST COMPANY et al.

No. 52096.

Supreme Court of Louisiana.

Feb. 11, 1972.

In re: Capital Bank & Trust Company applying for certiorari or writ of review, to the Court of Appeal, Second Circuit, Parish of Caddo. 255 So.2d 816.

It is ordered that the writ of review issue; that the Court of Appeal send up the record in duplicate of the case; and that counsel for plaintiff and defendant be notified.
#### Rose BRADWELL, a/k/a Rose Jones, Appellant, v. STATE of Florida, Appellee.

No. 77-954.

District Court of Appeal of Florida, Second District.

Dec. 16, 1977.

Jack 0. Johnson, Public Defender, Bar-tow, and Douglas A. Wallace, Asst. Public Defender, Bradenton, for appellant.

Robert L. Shevin, Atty. Gen., Tallahassee, and Richard G. Pippinger, Asst. Atty. Gen., Tampa, for appellee.

PER CURIAM.

The judgment appealed from is affirmed, but this case is remanded for resentencing of appellant. The present sentence does not specifically set forth the period of credit time to be allowed as required by Section 921.161(1), Florida Statutes (1975); *Brooks v. State,*349 So.2d 794 (Fla.2d DCA 1977). Moreover the phrase “at hard labor” in the sentence is improper. *Brooks v. State, supra.*The appellant does not have to be present at resentencing.

GRIMES, A. C. J., and SCHEB and OTT, JJ., concur.
No. 10614.

#### The Roby Coal Co. *v.*Hill.

Decided December 15, 1908.

Error to Circuit Court of Harrison ’county.

*Messrs. Perry & Rowland,*for plaintiff in error.

*Mr. Albert O. Barnes,*for defendant in error.

Judgment affirmed as to the judgment of reversal and the final judgment of circuit court reversed and cause remanded to court of common pleas for further proceedings according to law.

Price, C. J., Si-iauck, Crew, Summers, Spear and Davis, JJ., concur.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-1996
<PERIOD-START>                             JUL-01-1995
<PERIOD-END>                               JUN-30-1996
<CASH>                                         185,099
<SECURITIES>                                         0
<RECEIVABLES>                                   27,131
<ALLOWANCES>                                     3,400
<INVENTORY>                                     16,421
<CURRENT-ASSETS>                               225,251
<PP&E>                                       3,280,922
<DEPRECIATION>                                 528,217
<TOTAL-ASSETS>                               3,760,831
<CURRENT-LIABILITIES>                          553,240
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           113
<OTHER-SE>                                   3,207,478
<TOTAL-LIABILITY-AND-EQUITY>                 3,760,831
<SALES>                                        514,513
<TOTAL-REVENUES>                               514,513
<CGS>                                          414,633
<TOTAL-COSTS>                                  414,633
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 1,521
<INTEREST-EXPENSE>                              20,500
<INCOME-PRETAX>                              (893,621)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (893,621)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (893,621)
<EPS-PRIMARY>                                    (.08)
<EPS-DILUTED>                                    (.08)
        

</TABLE>